Table 1.
Maraviroc Switch Study Baseline Characteristics
| Characteristic | Control (n = 82)a | MVC + 2 N(t)RTIs (n = 156)a | MVC + PI/r (n = 157)a | Total (N = 395)a |
|---|---|---|---|---|
| Female, No. (%) | 20 (24.4) | 35 (22.4) | 35 (22.3) | 90 (22.8) |
| Age, y, mean (SD) | 43.6 (10.5) | 43.7 (10.5) | 42.7 (9.6) | 43.3 (10.1) |
| Ethnicity, No. (%) | ||||
| African heritage | 0 (0.0) | 6 (3.9) | 4 (2.6) | 10 (2.5) |
| Asian | 9 (11.0) | 10 (6.4) | 15 (9.6) | 34 (8.6) |
| Australian Aboriginal | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.3) |
| White | 42 (51.2) | 99 (63.5) | 80 (51.0) | 221 (56.0) |
| Hispanic or Latino | 31 (37.8) | 40 (25.6) | 56 (35.7) | 127 (32.2) |
| Other | 0 (0.0) | 1 (0.6) | 1 (0.6) | 2 (0.5) |
| CDC category C, No. (%) | 21 (25.6) | 36 (23.1) | 30 (19.1) | 87 (22.0) |
| Baseline HIV RNA <50 copies/mL | 96.3% | 96.8% | 95.5% | 96.2% |
| CD4+ T cells/µL, mean (SD) | 634.8 (244.5) | 596.3 (253.3) | 637.6 (252.7) | 617.0 (251.2) |
| Nadir CD4+ T cells/µL, mean (SD) | 258 (169) | 206 (156) | 238 (143) | 213 (162) |
| ART duration, y, mean (SD) | 6.3 (4.5) | 5.7 (3.8) | 6.4 (4.4) | 6.1 (4.2) |
| GFR, mL/min, mean (SD) | 99.39 (20.59) | 106.61 (71.77) (n = 155) | 100.73 (22.37) | 102.77 (48.11) (n = 394) |
| Total cholesterol, mmol/L, mean (SD) | 4.87 (1.1) (n = 79) | 4.89 (1.04) (n = 146) | 4.89 (1.01) (n = 155) | 4.89 (1.04) (n = 380) |
| LDL-c, mmol/L, mean (SD) | 2.82 (0.96) (n = 79) | 2.87 (0.86) (n = 142) | 2.86 (0.94) (n = 150) | 2.86 (0.91) (n = 371) |
| HDL-c, mmol/L, mean (SD) | 1.21 (0.29) (n = 79) | 1.26 (0.39) (n = 146) | 1.26 (0.41) (n = 155) | 1.25 (0.38) (n = 380) |
| TGs, mmol/L, mean (SD) | 1.91 (0.99) (n = 79) | 1.77 (0.93) (n = 144) | 1.98 (1.4) (n = 152) | 1.88 (1.16) (n = 375) |
| Right hip T-score, mean (SD) | −0.3 (1.28) (n = 76) | −0.71 (1.1) (n = 131) | −0.6 (1.04) (n = 143) | −0.58 (1.13) (n = 350) |
| Lumbar (T2–T4) T-score, mean (SD) | −0.75 (1.23) (n = 77) | −1.24 (1.35) (n = 134) | −1.18 (1.27) (n = 143) | −1.11 (1.3) (n = 354) |
Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; GFR, glomerular filtration rate; HDL-c, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; LDL-c, low-density lipoprotein cholesterol; MVC, maraviroc; N(t)RTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor; SD, standard deviation; TGs, triglycerides;
a If data are available for fewer participants, this will be indicated in brackets against each baseline characteristic.